Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR)Defense World · 2 days ago
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene TherapyMarketBeat · 3 days ago
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases TranscriptSeeking Alpha · 3 days ago
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PRNewsWire · Oct 12, 2026
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingPRNewsWire · Sep 24, 2026
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.08 | $0.43 | Beat |
| May 14, 2026 | -$1.36 | -$1.72 | Miss |
| Mar 5, 2026 | -$1.01 | -$1.30 | Miss |
| Nov 6, 2025 | -$1.38 | -$1.20 | Beat |
| Aug 7, 2025 | -$1.13 | -$1.38 | Miss |
| May 12, 2025 | $0.41 | $0.12 | Miss |